StarOne IP Group v. Cardinal Health: Formalin Container Patent Dispute Dismissed
StarOne Intellectual Property Group Ltd. filed suit against Cardinal Health, Inc. in Ohio’s Southern District Court, asserting US7475774B2 against the BiopSafe® Formalin Safety Container product line. The case was voluntarily dismissed without prejudice after 176 days — leaving the door open for future proceedings.
Formalin container IP dispute exits Ohio court in under six months
StarOne Intellectual Property Group Ltd., a patent assertion entity, filed case 2:24-cv-02852 in the Southern District of Ohio on 22 May 2024, asserting US7475774B2 against Cardinal Health, Inc. The accused products were Cardinal Health’s BiopSafe® Formalin Safety Container 20ml (model 3178-20000) and BiopSafe® Formalin Safety Container 60ml (model 3178-60000), used for the safe handling and transport of formalin-fixed tissue specimens in clinical and pathology settings.
The case closed on 14 November 2024 — 176 days after filing — when StarOne filed a notice of voluntary dismissal without prejudice pursuant to Fed. R. Civ. P. 41(a)(1). This procedural mechanism allows a plaintiff to exit a case unilaterally at an early stage, before the defendant has served an answer or a motion for summary judgment, without any court order required. Critically, a dismissal without prejudice does not constitute an adjudication on the merits, meaning StarOne retains the legal right to refile the same infringement claims against Cardinal Health.
The speed of the resolution — under six months — suggests the parties may not have reached the discovery phase, which is consistent with a Rule 41(a)(1) early exit. The public record does not disclose whether the dismissal followed settlement negotiations, a licensing discussion, or a unilateral strategic reassessment by StarOne. No damages, injunctive relief, or fee award is recorded. The absence of a merits ruling means Cardinal Health received no formal vindication, and the infringement question under US7475774B2 remains technically unresolved.
Filing to Voluntary dismissal in 176 days
176 days from filing to voluntary dismissal — shorter than median district court patent case
Voluntarily dismissed: what the Rule 41 exit means for both parties
Rule 41(a)(1): plaintiff’s unilateral early exit
Fed. R. Civ. P. 41(a)(1) permits a plaintiff to dismiss an action without a court order by filing a notice before the defendant serves an answer or motion for summary judgment. The dismissal takes effect immediately upon filing. It is a procedural exit, not a merits ruling — no judge evaluates the strength of either party’s position. This mechanism is frequently used when parties resolve disputes privately or when a plaintiff reassesses litigation strategy early.
No merits adjudicationPublic record confirms ‘without prejudice’ — refiling remains open
StarOne’s notice explicitly invokes dismissal without prejudice, meaning the infringement claims under US7475774B2 are not extinguished. StarOne retains the right to refile against Cardinal Health in any competent jurisdiction. This contrasts with a dismissal with prejudice, which would permanently bar the same claims. The without-prejudice designation preserves StarOne’s legal position entirely, and no inference about the merits of the infringement claim can be drawn from this outcome.
Refiling legally permissibleNo infringement finding — but no formal clearance either
Cardinal Health obtained a dismissal without expending resources on full discovery or trial, and with no adverse judgment on record. However, because the dismissal is without prejudice, Cardinal Health cannot treat this as a final resolution. The BiopSafe® Formalin Safety Container product line remains potentially at risk if StarOne or any future holder of US7475774B2 elects to refile. Cardinal Health may wish to conduct or update a freedom-to-operate analysis on the asserted patent to better understand its ongoing exposure.
Ongoing patent risk possibleUnresolved patent creates residual risk for formalin container market
US7475774B2 remains an active, unlitigated-to-conclusion patent covering formalin safety container technology. Any manufacturer, distributor, or purchaser of comparable specimen containment products should note that the merits of this patent have not been judicially tested. The without-prejudice dismissal means competitive uncertainty persists. Sector participants may consider monitoring StarOne’s litigation activity and the status of US7475774B2 for signs of renewed enforcement or licensing campaigns.
Sector-wide monitoring advisedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | StarOne Intellectual Property Group Ltd. | Company | Patent assertion entity — holder of US7475774B2 covering formalin safety containmentSearch in Eureka ↗ |
| Defendant | Cardinal Health, Inc. | Company | Cardinal Health, Inc. — global healthcare products and distribution companySearch in Eureka ↗ |
| Plaintiff counsel | Ariel Reinitz | Attorney | Counsel for StarOne Intellectual Property Group Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Meredith Rachel Lloyd | Attorney | Counsel for StarOne Intellectual Property Group Ltd.Search in Eureka ↗ |
| Plaintiff law firm | Bochner PLLC | Law Firm | Representing StarOne Intellectual Property Group Ltd.Search in Eureka ↗ |
| Defendant counsel | Kevin W. Kirsch. | Attorney | Counsel for Cardinal Health, Inc.Search in Eureka ↗ |
| Defendant law firm | Baker & Hostetler, LLP | Law Firm | Representing Cardinal Health, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Ohio Southern District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal notice invokes Fed. R. Civ. P. 41(a)(1) and expressly designates the dismissal as without prejudice. This is a procedural termination, not a substantive ruling — no court assessed the validity or infringement of US7475774B2. The without-prejudice designation is legally significant: it preserves StarOne’s right to refile identical claims, and it prevents Cardinal Health from invoking res judicata as a defence in any future action on the same patent. The public record provides no explanation for the timing of the exit.
US7475774B2 — Formalin safety container technology
US7475774B2, filed under application number US10/570599, protects technology relating to formalin safety containers — products designed to safely store, seal, and transport formalin-fixed biological specimens in clinical, surgical, and pathology environments. Formalin, a solution of formaldehyde, is classified as a hazardous chemical, and the safe containment of specimens preserved in formalin is a regulatory and occupational health priority in healthcare settings. The patent’s claims likely address structural or functional innovations in container design that reduce exposure risk.
In the context of the cardinal health dispute, the patent was asserted against two specific BiopSafe® SKUs at 20ml and 60ml volumes — product sizes commonly used in surgical biopsy and pathology workflows. This patent potentially represents a meaningful enforcement asset in the specimen containment market, where a small number of manufacturers supply a large proportion of hospital and laboratory procurement. Any company designing or sourcing formalin safety containers should treat US7475774B2 as an active risk asset until its claims are adjudicated or it expires.
Should your team run an FTO against US7475774B2?
Any company that manufactures, imports, distributes, or procures formalin safety containers — including 20ml and 60ml specimen containers used in biopsy and pathology workflows — should assess freedom-to-operate against US7475774B2. The without-prejudice dismissal of this case means the patent has not been invalidated or found non-infringed. Product teams developing next-generation specimen containment solutions, or procurement teams evaluating alternative suppliers to Cardinal Health’s BiopSafe® line, face direct and immediate relevance from this patent’s claim scope.
PatSnap Eureka’s FTO Search Agent can map the independent and dependent claims of US7475774B2 against your specific product specifications, flag continuation and divisional family members that may extend the patent’s effective enforcement window, and surface prior art that could support an invalidity argument if the patent is reasserted. Eureka also enables real-time monitoring of the patent’s assignment and licensing history, so you receive alerts if StarOne transfers the asset or files new actions — ensuring your legal and product teams stay ahead of enforcement risk.
Run a freedom-to-operate analysis on US7475774B2 to assess your product’s exposure
Run FTO in Eureka →Similar formalin container and medical device patent cases in US district courts
Explore comparable patent infringement actions in the medical device and specimen containment sector filed in US district courts, including cases involving hazardous material container patents and healthcare product assertion entities.
What this case signals for the medical device container IP landscape
A rapid Rule 41 exit without prejudice in a formalin container patent case raises questions about enforcement strategy and residual exposure for healthcare product companies.
Without-prejudice exits preserve optionality — monitor StarOne’s next move
StarOne’s Rule 41(a)(1) dismissal without prejudice is not a concession. Patent assertion entities frequently use early dismissals to reset positioning — for licensing leverage, venue selection, or claim refinement. IP professionals tracking Cardinal Health or the formalin safety container space should monitor US7475774B2 for any continuation filings, assignment activity, or new litigation within the applicable statute of limitations.
Cardinal Health’s BiopSafe® line remains exposed without a merits ruling
No court has ruled that BiopSafe® Formalin Safety Containers do not infringe US7475774B2. In-house IP teams at Cardinal Health and comparable healthcare product companies should ensure their FTO analysis on this patent is current. If a licensing demand preceded the dismissal, the commercial terms — and any implied clearance — would be entirely private and unenforceable against third parties.
StarOne v Cardinal — key questions answered
StarOne Intellectual Property Group Ltd. filed a patent infringement action against Cardinal Health, Inc. in the Southern District of Ohio on 22 May 2024, asserting US7475774B2 against Cardinal Health’s BiopSafe® Formalin Safety Containers. The case was voluntarily dismissed without prejudice by StarOne on 14 November 2024, 176 days after filing, with no merits ruling recorded.
A dismissal without prejudice under Fed. R. Civ. P. 41(a)(1) means StarOne’s infringement claims were not adjudicated on the merits. StarOne retains the right to refile the same claims against Cardinal Health in the future. Cardinal Health received no formal finding of non-infringement, and the patent US7475774B2 remains active and enforceable against other parties as well.
The complaint identified two specific products: the BiopSafe® Formalin Safety Container 20ml (model number 3178-20000) and the BiopSafe® Formalin Safety Container 60ml (model number 3178-60000). These are specimen containment products used in clinical and pathology settings to safely handle formalin-fixed tissue samples.
US7475774B2 is a United States patent filed under application number US10/570599, held by StarOne Intellectual Property Group Ltd. at the time of litigation. It covers technology related to formalin safety containers — products engineered to safely store and transport hazardous formalin solutions used to preserve biological specimens. The precise claim scope would require a full prosecution history review to assess the actual infringement perimeter.
Yes. Because the dismissal was entered without prejudice, StarOne is not legally barred from refiling the same patent infringement claims against Cardinal Health based on US7475774B2. There is no public record indicating a settlement, licence, or any agreement that would restrict StarOne’s ability to pursue future enforcement. Cardinal Health’s exposure under this patent should be considered ongoing until the patent expires or is invalidated.
PatSnap Eureka searches patents and litigation data to answer instantly.